Skip to main content
Krystal Biotech touts efficacy of wound closure gene therapy candidate
6/26/2019

KB103, Krystal Biotech's lead gene therapy for recessive dystrophic epidermolysis bullosa, exhibited efficacy in healing wounds caused by the disorder after it reported full closure of five lesions by the 90th day after treatment based on data from its Phase I/II GEM trial. Krystal also disclosed that KB103 has been granted a regenerative medicine advanced therapy designation by the FDA.

Full Story: